B‐cell depletion with anti‐CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor‐β receptor II dominant negative mice†

These data suggest potential usage of anti-CD20 in early PBC resistant to other modalities, but raise a cautionary note regarding the use of anti-CD20 in inflammatory bowel disease.